Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

BACKGROUND: The China Continuation study was a separate regional expansion of the global, double-blind, placebo-controlled, randomized phase III TOURMALINE-MM1 study of ixazomib plus lenalidomide–dexamethasone (Rd) in patients with relapsed/refractory multiple myeloma (RRMM) following one to three p...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Hematol Oncol
Päätekijät: Hou, Jian, Jin, Jie, Xu, Yan, Wu, Depei, Ke, Xiaoyan, Zhou, Daobin, Lu, Jin, Du, Xin, Chen, Xiequn, Li, Junmin, Liu, Jing, Gupta, Neeraj, Hanley, Michael J., Li, Hongmei, Hua, Zhaowei, Wang, Bingxia, Zhang, Xiaoquan, Wang, Hui, van de Velde, Helgi, Richardson, Paul G., Moreau, Philippe
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2017
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5500972/
https://ncbi.nlm.nih.gov/pubmed/28683766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-017-0501-4
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia